BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12745271)

  • 1. High-dose therapy with autologous transplantation for Hodgkin's disease: the Bologna experience.
    Zinzani PL; Tani M; Gabriele A; Gherlinzoni F; de Vivo A; Ricci P; Bandini G; Lemoli RM; Motta MR; Rizzi S; Giudice V; Zompatori M; Stefoni V; Alinari L; Musuraca G; Bassi S; Conte R; Pileri S; Tura S; Baccarani M
    Haematologica; 2003 May; 88(5):522-8. PubMed ID: 12745271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
    Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
    Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: atopy predicts idiopathic diffuse lung injury syndromes.
    Frankovich J; Donaldson SS; Lee Y; Wong RM; Amylon M; Verneris MR
    Biol Blood Marrow Transplant; 2001; 7(1):49-57. PubMed ID: 11215699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of autologous stem cell transplantation for Hodgkin's disease (HD) and low-/intermediate-grade B non-Hodgkin's lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR).
    Nachbaur D; Greinix HT; Koller E; Krieger O; Linkesch W; Kasparu H; Pober M; Hinterberger W; Hausmaninger H; Heistinger M; Ulsperger E; Karlhuber S; Schwinger W; Lindner B
    Ann Hematol; 2005 Jul; 84(7):462-73. PubMed ID: 15726362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C; Cuttica A; Vitolo U; Liberati M; Di Nicola M; Cortelazzo S; Rosato R; Rosanelli C; Di Renzo N; Musso M; Pavone E; Santini G; Pescarollo A; De Crescenzo A; Federico M; Gallamini A; Pregno P; Romano R; Coser P; Gallo E; Boccadoro M; Barbui T; Pileri A; Gianni AM; Levis A
    Cancer; 2003 Jun; 97(11):2748-59. PubMed ID: 12767087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy.
    Vigouroux S; Milpied N; Andrieu JM; Colonna P; Ifrah N; Colombat P; Desablens B; Abgrall JF; Casassus P; Guilhot F; Briere J; Le Mevel A; Moreau P; Mechinaud F; Mahe B; Morineau N; Vigier M; Rapp MJ; Harousseau JL
    Bone Marrow Transplant; 2002 May; 29(10):833-42. PubMed ID: 12058233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.
    Lieskovsky YE; Donaldson SS; Torres MA; Wong RM; Amylon MD; Link MP; Agarwal R
    J Clin Oncol; 2004 Nov; 22(22):4532-40. PubMed ID: 15542804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with autologous transplantation for aggressive non-Hodgkin's lymphoma: the Bologna experience.
    Zinzani PL; Tani M; Gabriele A; Gherlinzoni F; De Vivo A; Ricci P; Bandini G; Lemoli RM; Motta MR; Rizzi S; Guidice V; Zompatori M; Stefoni V; Alinari L; Musuraca G; Marchi E; Bassi S; Conte R; Pileri S; Tura S; Baccarani M
    Leuk Lymphoma; 2004 Feb; 45(2):321-6. PubMed ID: 15101718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA; Saito NG; Ratanatharathorn V; Uberti JP; Adams PT; Ayash LJ; Reynolds CM; Silver SM; Schipper MJ; Lichter AS; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):208-18. PubMed ID: 15093918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
    Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
    Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
    Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
    J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
    Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
    Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers.
    van Kempen-Harteveld ML; Brand R; Kal HB; Verdonck LF; Hofman P; Schattenberg AV; van der Maazen RW; Cornelissen JJ; Eijkenboom WM; van der Lelie JP; Oldenburger F; Barge RM; van Biezen A; Vossen JM; Noordijk EM; Struikmans H
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1444-54. PubMed ID: 18294781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
    Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
    Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
    Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma.
    Popat U; Hosing C; Saliba RM; Anderlini P; van Besien K; Przepiorka D; Khouri IF; Gajewski J; Claxton D; Giralt S; Rodriguez M; Romaguera J; Hagemeister F; Ha C; Cox J; Cabanillas F; Andersson BS; Champlin RE
    Bone Marrow Transplant; 2004 May; 33(10):1015-23. PubMed ID: 15048145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral blood stem cell versus autologous bone marrow transplantation for Hodgkin's disease: equivalent survival outcome in a single-centre matched-pair analysis.
    Perry AR; Peniket AJ; Watts MJ; Leverett D; Goldstone AH; Linch DC
    Br J Haematol; 1999 Apr; 105(1):280-7. PubMed ID: 10233395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.